Advertisement

Clinical Syndromes: Candida and Candidosis

  • Markus Ruhnke
Chapter

Abstract

The term candidosis or candidiasis comprises several categories of infection: systemic or invasive Candida infections/diseases (IC), such as acute disseminated candidosis, chronic disseminated candidosis (CDC) and candidaemia as well as superficial (muco-cutaneous) Candida infections. According to the recent consensus definition the term “fungal infection” should be replaced by “fungal disease”. Candidaemia is the most frequent manifestation of systemic Candida infection. The serious prognosis associated with candidaemia is highlighted by a recent survey of 60 cases with candidaemia due to C. albicans (n = 38) and non-C. albicans (n = 22): 8% developed severe sepsis and 27% septic shock. The all-cause mortality was 42%. Candidaemia is most often observed in non-granulocytopenic patients after abdominal surgery or catheter-related infection with secondary blood stream infection. Potential further manifestations of invasive disease are Candida oesophagitis (in the past often classified as muco-cutaneous candidosis), peritonitis, urinary tract infections. Less frequently, endocarditis, meningitis/meningoencephalitis or osteomyelitis are manifestations of acute disseminated candidosis.

References

  1. 1.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503–535PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    dePauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821CrossRefGoogle Scholar
  3. 3.
    Wisplinghoff H, Seifert H, Coimbra M, Wenzel RP, Edmond MB (2001) Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Staphylococcus aureus. Clin Infect Dis 33(5):733–736PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C et al (2011) Ocular manifestations of candidemia. Clin Infect Dis 53(3):262–268PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW et al (2000) Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 30(1):14–18PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE et al (2009) Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 35(9):1526–1531PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glockner A, Heinz W et al (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54(4):279–310PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133–163PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Ruhnke M (2006) Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 7(4):495–504PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Greenspan D, Greenspan JS (1996) HIV-related oral disease. Lancet 348(9029):729–733PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Gottfredsson M, Cox GM, Indridason OS, de Almeida GM, Heald AE, Perfect JR (1999) Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 180(2):534–537PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Martins MD, Lozano-Chiu M, Rex JH (1998) Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 27(5):1291–1294PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Vazquez JA, Sobel JD, Peng G, Steele-Moore L, Schuman P, Holloway W et al (1999) Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis 28(5):1025–1031PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC et al (2006) Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44(10):3551–3556PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S et al (2008) Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46(2):515–521PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL et al (2006) Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44(10):3578–3582PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN (2010) Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 68(3):278–283PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M et al (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43(4):1829–1835PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD et al (2013) Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 19(8):E343–E353PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Bassetti M, Merelli M, Righi E, Az-Martin A, Rosello EM, Luzzati R et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 6(9):e24198Google Scholar
  21. 21.
    Borg-von-Zepelin M, Kunz L, Ruchel R, Reichard U, Weig M, Gross U (2007) Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 60(2):424–428PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B et al (2015) Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). Clin Microbiol Infect 21(1):87PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Presterl E, Daxbock F, Graninger W, Willinger B (2007) Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin Microbiol Infect 13(11):1072–1076PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Colombo AL, Melo AS, Crespo Rosas RF, Salomao R, Briones M, Hollis RJ et al (2003) Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 46(4):253–257PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ et al (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48(12):1695–1703PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M (2011) Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 55(2):561–566PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ et al (2001) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39(9):3254–3259PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP et al (2017) Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64(2):134–140PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L et al (2013) Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 68(2):438–443PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Guitard J, Angoulvant A, Letscher-Bru V, L’ollivier C, Cornet M, Dalle F et al (2013) Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature. Med Mycol 51(8):795–799PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Meis JF, Ruhnke M, de Pauw BE, Odds FC, Siegert W, Verweij PE (1999) Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5(1):150–153PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Hirayama T, Miyazaki T, Yamagishi Y, Mikamo H, Ueda T, Nakajima K et al (2018) Clinical and microbiological characteristics of Candida guilliermondii and Candida fermentati. Antimicrob Agents Chemother 62(6):e02528PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Liu WL, Lai CC, Li MC, Wu CJ, Ko WC, Hung YL et al (2017) Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007–2014. J Microbiol Immunol Infect.  https://doi.org/10.1016/j.jmii.2017.08.007
  34. 34.
    Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J et al (2016) Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus - United States, May 2013-August 2016. Morb Mortal Wkly Rep 65(44):1234–1237CrossRefGoogle Scholar
  35. 35.
    Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F et al (2016) First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 73(4):369–374PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Chowdhary A, Voss A, Meis JF (2016) Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J Hosp Infect 94(3):209–212PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    McCarthy M (2016) Hospital transmitted Candida auris infections confirmed in the US. BMJ 355:i5978PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Morales-Lopez SE, Parra-Giraldo CM, Ceballos-Garzon A, Martinez HP, Rodriguez GJ, Varez-Moreno CA et al (2017) Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia. Emerg Infect Dis 23(1):162–164PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A et al (2016) First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5:35PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Zhang L, Xiao M, Wang H, Gao R, Fan X, Brown M et al (2014) Yeast identification algorithm based on use of the Vitek MS system selectively supplemented with ribosomal DNA sequencing: proposal of a reference assay for invasive fungal surveillance programs in China. J Clin Microbiol 52(2):572–577PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Dorgan E, Denning DW, McMullan R (2015) Burden of fungal disease in Ireland. J Med Microbiol 64(Pt 4):423–426PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Gugnani HC, Denning DW (2015) Burden of serious fungal infections in the Dominican Republic. J Infect Public Health 9(1):7–12PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Mortensen KL, Denning DW, Arendrup MC (2015) The burden of fungal disease in Denmark. Mycoses 58(Suppl 5):15–21PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Oladele RO, Denning DW (2014) Burden of serious fungal infection in Nigeria. West Afr J Med 33(2):107–114PubMedPubMedCentralGoogle Scholar
  45. 45.
    Rodriguez-Tudela JL, Astruey-Izquierdo A, Gago S, Cuenca-Estrella M, Leon C, Miro JM et al (2015) Burden of serious fungal infections in Spain. Clin Microbiol Infect 21(2):183–189PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H et al (2015) Estimated burden of fungal infections in Germany. Mycoses 58(Suppl 5):22–28PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Ben R, Denning DW (2015) Estimating the burden of fungal diseases in Israel. Isr Med Assoc J 17(6):374–379PubMedPubMedCentralGoogle Scholar
  48. 48.
    Chrdle A, Mallatova N, Vasakova M, Haber J, Denning DW (2015) Burden of serious fungal infections in the Czech Republic. Mycoses 58(Suppl 5):6–14PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Corzo-Leon DE, Rmstrong-James D, Denning DW (2015) Burden of serious fungal infections in Mexico. Mycoses 58(Suppl 5):34–44PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Klimko N, Kozlova Y, Khostelidi S, Shadrivova O, Borzova Y, Burygina E et al (2015) The burden of serious fungal diseases in Russia. Mycoses 58(Suppl 5):58–62PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Lagrou K, Maertens J, Van EE, Denning DW (2015) Burden of serious fungal infections in Belgium. Mycoses 58(Suppl 5):1–5PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Pegorie M, Denning DW, Welfare W (2016) Estimating the burden of invasive and serious fungal disease in the United Kingdom. J Infect 74(1):60–71PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317CrossRefGoogle Scholar
  54. 54.
    Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB et al (2014) Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 43(1):78–81PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Ylipalosaari P, La-Kokko TI, Karhu J, Koskela M, Laurila J, Ohtonen P et al (2012) Comparison of the epidemiology, risk factors, outcome and degree of organ failures of patients with candidemia acquired before or during ICU treatment. Crit Care 16(2):R62PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35(5):627–630PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA et al (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33(2):177–186PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Leleu G, Aegerter P, Guidet B (2002) Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 17(3):168–175PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO, Sohn AH, Levine GL, Siegel JD et al (2002) A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J Pediatr 140(4):432–438PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34(2):344–353PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH et al (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274(8):639–644PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Geffers C, Zuschneid I, Sohr D, Ruden H, Gastmeier P (2004) Microbiological isolates associated with nosocomial infections in intensive care units: data of 274 intensive care units participating in the German Nosocomial Infections Surveillance System (KISS). Anasthesiol Intensivmed Notfallmed Schmerzther 39(1):15–19PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J et al (2004) Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 38(3):311–320PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Mean M, Marchetti O, Calandra T (2008) Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 12(1):204PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonheyder HC, Knudsen JD, Jensen IM et al (2008) Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 14(5):487–494PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G (2004) A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 36(1):52–55PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P (2003) Candidemia in Finland, 1995-1999. Emerg Infect Dis 9(8):985–990PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P (2006) Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44(6):1977–1981PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B et al (2005) Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43(9):4434–4440PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Baldesi O, Bailly S, Ruckly S, Lepape A, L'Heriteau F, Aupee M et al (2017) ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013 - a study from the REA-RAISIN network. J Infect 75(1):59–67PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C et al (2015) Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis 61(3):324–331PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B et al (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28(5):1071–1079PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 56(2):126–129PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD (2010) Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48(7):2373–2380PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55(2):532–538PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM et al (2017) Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol 153(5):406–412PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Seebacher C, Abeck D, Brasch J, Effendy I, Ginter-Hanselmayer G, Haake N et al (2006) Candidiasis of the skin. J Dtsch Dermatol Ges 4(7):591–596PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H et al (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282(23):2220–2226PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K et al (2013) Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/OAG) (AWMF 055/066). Infection 41(Suppl 2):S91–S115PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G et al (2015) Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 58(Suppl 1):1–15PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G, Gonzalez Lopez A, Alvarez Navia F, Ochoa Sangrador C et al (2000) Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis 19(2):96–100PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Kirkpatrick CH (2001) Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 20(2):197–206PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Glocker E, Grimbacher B (2010) Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Curr Opin Allergy Clin Immunol 10(6):542–550PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova JL et al (2013) Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr 25(6):736–747PubMedPubMedCentralGoogle Scholar
  86. 86.
    Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK et al (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332(6025):65–68PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U et al (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 361(18):1727–1735PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D et al (2007) Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 44(4):607–614PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Firinu D, Massidda O, Lorrai MM, Serusi L, Peralta M, Barca MP et al (2011) Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole. Clin Dev Immunol 2011:283239PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Bodey GP, Anaissie EJ, Edwards JE Jr (1993) Definitions of Candida infections. In: Bodey GP (ed) Candidiasis. Raven Press, Ltd., New York, pp 407–408Google Scholar
  91. 91.
    Hof H (2010) IFI = invasive fungal infections. What is that? A misnomer, because a non-invasive fungal infection does not exist! Int J Infect Dis 14(6):e458–e459PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7–14PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220(6):751–758PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Solomkin JS (1996) Timing of treatment for nonneutropenic patients colonized with Candida. Am J Surg 172(6A):44S–48SPubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3(12):772–785PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Playford EG, Lipman J, Kabir M, McBryde ES, Nimmo GR, Lau A et al (2009) Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 35(12):2141–2145PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L et al (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32(12):2443–2449PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Hall AM, Poole LA, Renton B, Wozniak A, Fisher M, Neal T et al (2013) Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis. Crit Care 17(2):R49PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Varez-Lerma F et al (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34(3):730–737PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26(4):271–276PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37(5):1624–1633PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C et al (2009) Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54(1):46–51CrossRefGoogle Scholar
  103. 103.
    Kratzer C, Graninger W, Lassnigg A, Presterl E (2011) Design and use of Candida scores at the intensive care unit. Mycoses 54(6):467–474PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP et al (2009) Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37(5):1612–1618PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Lortholary O, Renaudat C, Sitbon K, Madec Y, Oeud-Ndam L, Wolff M et al (2014) Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 40(9):1303–1312PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Eggimann P, Ostrosky-Zeichner L (2010) Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care 16(5):465–469PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 373(15):1445–1456PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Eggimann P, Pittet D (2014) Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med 40(10):1429–1448PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3(11):685–702PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54(12):1739–1746PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM et al (1992) Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14(4):875–883PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE et al (1995) Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 21(4):994–996PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M et al (2004) Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38(8):1119–1127PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN et al (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51(3):295–303PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Wenzel RP, Gennings C (2005) Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 41(Suppl 6):S389–S393PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Labelle AJ, Micek ST, Roubinian N, Kollef MH (2008) Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36(11):2967–2972PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Anaissie EJ, Rex JH, Uzun O, Vartivarian S (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104(3):238–245PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Raad I, Hanna H, Maki D (2007) Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 7(10):645–657PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Wolf HH, Leithauser M, Maschmeyer G, Salwender H, Klein U, Chaberny I et al (2008) Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 87(11):863–876PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):409–417PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, Kontoyiannis DP et al (2016) Candida arthritis: analysis of 112 pediatric and adult cases. Open Forum Infect Dis 3(1):ofv207PubMedPubMedCentralGoogle Scholar
  122. 122.
    Gamaletsou MN, Kontoyiannis DP, Sipsas NV, Moriyama B, Alexander E, Roilides E et al (2012) Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). Clin Infect Dis 55(10):1338–1351PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Richaud C, De Lastours V, Panhard X, Petrover D, Bruno F, Lefort A (2017) Candida vertebral osteomyelitis (CVO) 28 cases from a 10-year retrospective study in France. Medicine 96(31):e7525PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Stolberg-Stolberg J, Horn D, Rosslenbroich S, Riesenbeck O, Kampmeier S, Mohr M et al (2017) Management of destructive Candida albicans spondylodiscitis of the cervical spine: a systematic analysis of literature illustrated by an unusual case. Eur Spine J 26(4):1009–1018PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Viale P (2009) Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs 69(Suppl 1):51–57PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Sobel JD, Fisher JF, Kauffman CA, Newman CA (2011) Candida urinary tract infections--epidemiology. Clin Infect Dis 52(Suppl 6):S433–S436PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Drogari-Apiranthitou M, Anyfantis I, Galani I, Kanioura L, Daikos GL, Petrikkos G (2017) Association between candiduria and candidemia: a clinical and molecular analysis of cases. Mycopathologia 182(11-12):1045–1052PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Kauffman CA, Fisher JF, Sobel JD, Newman CA (2011) Candida urinary tract infections--diagnosis. Clin Infect Dis 52(Suppl 6):S452–S456PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Fisher JF, Sobel JD, Kauffman CA, Newman CA (2011) Candida urinary tract infections--treatment. Clin Infect Dis 52(Suppl 6):S457–S466PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Tuon FF, Amato VS, Penteado F Sr (2009) Bladder irrigation with amphotericin B and fungal urinary tract infection--systematic review with meta-analysis. Int J Infect Dis 13(6):701–706PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Sullivan KA, Caylor MM, Lin FC, Campbell-Bright S (2017) Comparison of amphotericin B bladder irrigations versus fluconazole for the treatment of candiduria in intensive care unit patients. J Pharm Pract 30(3):347–352PubMedCrossRefGoogle Scholar
  132. 132.
    Brooks RG (1989) Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 149(10):2226–2228PubMedCrossRefGoogle Scholar
  133. 133.
    Parke DW, Jones DB, Gentry LO (1982) Endogenous endophthalmitis among patients with candidemia. Ophthalmology 89(7):789–796PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Kato H, Yoshimura Y, Suido Y, Ide K, Sugiyama Y, Matsuno K et al (2018) Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection. Infection.  https://doi.org/10.1007/s15010-018-1163-zPubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS et al (2005) A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 51(3):230–247PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Pierrotti LC, Baddour LM (2002) Fungal endocarditis, 1995-2000. Chest 122(1):302–310PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W (2001) Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 32(1):50–62PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Baddley JW, Benjamin DK Jr, Patel M, Miro J, Athan E, Barsic B et al (2008) Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 27(7):519–529PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Smego RA Jr, Ahmad H (2011) The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine 90(4):237–249PubMedCrossRefGoogle Scholar
  140. 140.
    Lewis JH, Patel HR, Zimmerman HJ (1982) The spectrum of hepatic candidiasis. Hepatology 2(4):479–487PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Jones JM (1981) Granulomatous hepatitis due to Candida albicans in patients with acute leukemia. Ann Intern Med 94(4 pt 1):475–477PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Tashjian LS, Abramson JS, Peacock JE Jr (1984) Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients. Rev Infect Dis 6(5):689–703PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Haron E, Feld R, Tuffnell P, Patterson B, Hasselback R, Matlow A (1987) Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 83(1):17–26PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA (1988) Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 108(1):88–100PubMedCrossRefGoogle Scholar
  145. 145.
    Blade J, Lopez-Guillermo A, Rozman C, Granena A, Bruguera M, Bordas J et al (1992) Chronic systemic candidiasis in acute leukemia. Ann Hematol 64(5):240–244PubMedCrossRefGoogle Scholar
  146. 146.
    Woolley I, Curtis D, Szer J, Fairley C, Vujovic O, Ugoni A et al (1997) High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia. Leuk Lymphoma 27(5-6):469–474PubMedCrossRefGoogle Scholar
  147. 147.
    Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P (1997) Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 24(3):375–380PubMedCrossRefGoogle Scholar
  148. 148.
    Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP (2000) Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin N Am 14(3):721–739CrossRefGoogle Scholar
  149. 149.
    Chen CY, Chen YC, Tang JL, Yao M, Huang SY, Tsai W et al (2003) Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol 82(2):93–97PubMedCrossRefGoogle Scholar
  150. 150.
    Masood A, Sallah S (2005) Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 29(5):493–501PubMedCrossRefGoogle Scholar
  151. 151.
    Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA (1986) Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 159(2):349–353PubMedCrossRefGoogle Scholar
  152. 152.
    Semelka RC, Shoenut JP, Greenberg HM, Bow EJ (1992) Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging 2(3):341–345PubMedCrossRefGoogle Scholar
  153. 153.
    Teyton P, Baillet G, Hindie E, Filmont JE, Sarandi F, Toubert ME et al (2009) Hepatosplenic candidiasis imaged with F-18 FDG PET/CT. Clin Nucl Med 34(7):439–440PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    Johnson TL, Barnett JL, Appelman HD, Nostrant T (1988) Candida hepatitis. Histopathologic diagnosis. Am J Surg Pathol 12(9):716–720PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Fleischhacker M, Schulz S, Johrens K, von Lilienfeld-Toal M, Held T, Fietze E et al (2011) Diagnosis of chronic disseminated candidosis from liver biopsies by a novel PCR in patients with haematological malignancies. Clin Microbiol Infect 18(10):1010–1016PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Gupta AO, Singh N (2011) Immune reconstitution syndrome and fungal infections. Curr Opin Infect Dis 24(6):527–533PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Hu Z, Wei H, Meng F, Xu C, Cheng C, Yang Y (2013) Recurrent cryptococcal immune reconstitution inflammatory syndrome in an HIV-infected patient after anti-retroviral therapy: a case report. Ann Clin Microbiol Antimicrob 12:40PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19(10):1043–1049PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Jang YR, Kim MC, Kim T, Chong YP, Lee SO, Choi SH et al (2018) Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy. Med Mycol 56(6):782–786PubMedCrossRefGoogle Scholar
  160. 160.
    Legrand F, Lecuit M, Dupont B, Bellaton E, Huerre M, Rohrlich PS et al (2008) Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 46(5):696–702PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Lortholary O, Petrikkos G, Akova M, Arendrup MC, Rikan-Akdagli S, Bassetti M et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18(Suppl 7):68–77PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Cohen R, Roth FJ, Delgado E, Ahearn DG, Kalser MH (1969) Fungal flora of the normal human small and large intestine. N Engl J Med 280(12):638–641PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH et al (2013) A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 39(12):2092–2106PubMedCrossRefGoogle Scholar
  164. 164.
    Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M et al (2015) A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41(9):1601–1610PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Sandven P, Qvist H, Skovlund E, Giercksky KE (2002) Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 30(3):541–547PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH (2009) The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 37(6):522–527PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 17(7):1061–1067PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Lagunes L, Rey-Perez A, Martin-Gomez MT, Vena A, de Egea V, Munoz P et al (2017) Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain. Eur J Clin Microbiol Infect Dis 36(1):95–104PubMedCrossRefPubMedCentralGoogle Scholar
  169. 169.
    Montravers P, Perrigault PF, Timsit JF, Mira JP, Lortholary O, Leroy O et al (2017) Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin Microbiol Infect 23(2):117PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ (2000) The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 37(3):169–179PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    O'Brien D, Stevens NT, Lim CH, O’Brien DF, Smyth E, Fitzpatrick F et al (2011) Candida infection of the central nervous system following neurosurgery: a 12-year review. Acta Neurochir 153(6):1347–1350PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Nguyen MH, Yu VL (1995) Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 21(2):323–327PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Fernandez M, Moylett EH, Noyola DE, Baker CJ (2000) Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 31(2):458–463PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Faix RG (1984) Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 105(4):616–622PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Barton M, O'Brien K, Robinson JL, Davies DH, Simpson K, Asztalos E et al (2014) Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. BMC Infect Dis 14:327PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Montero A, Romero J, Vargas JA, Regueiro CA, Sanchez-Aloz G, De PF et al (2000) Candida infection of cerebrospinal fluid shunt devices: report of two cases and review of the literature. Acta Neurochir 142(1):67–74PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Lanternier F, Mahdaviani SA, Barbati E, Chaussade H, Koumar Y, Levy R et al (2015) Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol 135(6):1558–1568PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Friedman S, Richardson SE, Jacobs SE, O’Brien K (2000) Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 19(6):499–504PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    Hagensee ME, Bauwens JE, Kjos B, Bowden RA (1994) Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 19(3):402–408PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    Gavino C, Cotter A, Lichtenstein D, Lejtenyi D, Fortin C, Legault C et al (2014) CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis 59(1):81–84PubMedPubMedCentralCrossRefGoogle Scholar
  181. 181.
    Sundaram C, Umabala P, Laxmi V, Purohit AK, Prasad VS, Panigrahi M et al (2006) Pathology of fungal infections of the central nervous system: 17 years’ experience from Southern India. Histopathology 49(4):396–405PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Pendlebury WW, Perl DP, Munoz DG (1989) Multiple microabscesses in the central nervous system: a clinicopathologic study. J Neuropathol Exp Neurol 48(3):290–300PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael SW et al (2017) 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis.  https://doi.org/10.1093/cid/ciw861PubMedCentralCrossRefGoogle Scholar
  184. 184.
    Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 18(Suppl 7):38–52PubMedCrossRefPubMedCentralGoogle Scholar
  185. 185.
    Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O et al (2016) CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 27(7):1207–1225PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):e1–e50PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST et al (2004) Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol 42(12):5950–5953PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Flattery AM, Hickey E, Gill CJ, Powles MA, Misura AS, Galgoci AM et al (2011) Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. Antimicrob Agents Chemother 55(7):3491–3497PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I (2006) Epidemiology of visceral mycoses in patients with leukemia and MDS - analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Nippon Ishinkin Gakkai Zasshi 47(1):15–24CrossRefGoogle Scholar
  190. 190.
    von EM, Zuhlsdorf M, Roos N, Hesse M, Schulten R, van de Loo J (1995) Pulmonary fungal infections in patients with hematological malignancies--diagnostic approaches. Ann Hematol 70(3):135–141CrossRefGoogle Scholar
  191. 191.
    Blaschke S, Don M, Schillinger W, Ruchel R (2002) Candida pneumonia in patients without definitive immunodeficiency. Mycoses 45(Suppl 3):22–26PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC (2001) Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 120(1):177–184PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Dermawan JKT, Ghosh S, Keating MK, Gopalakrishna KV, Mukhopadhyay S (2018) Candida pneumonia with severe clinical course, recovery with antifungal therapy and unusual pathologic findings: a case report. Medicine 97(2):e9650PubMedPubMedCentralCrossRefGoogle Scholar
  194. 194.
    Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M (1999) Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 37(6):1732–1738PubMedPubMedCentralGoogle Scholar
  195. 195.
    Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I (2003) Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 53(11):744–750PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91(7):986–989PubMedPubMedCentralGoogle Scholar
  197. 197.
    Donhuijsen K, Petersen P, Schmid WK (2008) Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005. Dtsch Arztebl Int 105(28-29):501–506PubMedPubMedCentralGoogle Scholar
  198. 198.
    Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D (2010) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 61(3):259–265PubMedCrossRefPubMedCentralGoogle Scholar
  199. 199.
    Suzuki Y, Kume H, Togano T, Kanoh Y, Ohto H (2013) Epidemiology of visceral mycoses in autopsy cases in Japan: the data from 1989 to 2009 in the annual of pathological autopsy cases in Japan. Med Mycol 51(5):522–526PubMedCrossRefPubMedCentralGoogle Scholar
  200. 200.
    Delisle MS, Williamson DR, Albert M, Perreault MM, Jiang X, Day AG et al (2011) Impact of Candida species on clinical outcomes in patients with suspected ventilator-associated pneumonia. Can Respir J 18(3):131–136PubMedPubMedCentralCrossRefGoogle Scholar
  201. 201.
    Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK (2008) The clinical significance of Candida colonization of respiratory tract secretions in critically ill patients. J Crit Care 23(1):11–17PubMedCrossRefPubMedCentralGoogle Scholar
  202. 202.
    el-Ebiary M, Torres A, Fabregas N, de la Bellacasa JP, Gonzalez J, Ramirez J et al (1997) Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 156(2 Pt 1):583–590PubMedCrossRefPubMedCentralGoogle Scholar
  203. 203.
    Garnacho-Montero J, Olaechea P, varez-Lerma F, varez-Rocha L, Blanquer J, Galvan B et al (2013) Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter 26(2):173–188PubMedPubMedCentralGoogle Scholar
  204. 204.
    Clancy CJ, Nguyen MH, Morris AJ (1997) Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis 25(3):608–613PubMedCrossRefPubMedCentralGoogle Scholar
  205. 205.
    Kofteridis DP, Mantadakis E, Karatzanis AD, Bourolias CA, Papazoglou G, Velegrakis GA et al (2008) Non-Candida albicans Candida mediastinitis of odontogenic origin in a diabetic patient. Med Mycol 46(4):345–348PubMedCrossRefPubMedCentralGoogle Scholar
  206. 206.
    Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43(1):25–31PubMedCrossRefPubMedCentralGoogle Scholar
  207. 207.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640–3645PubMedPubMedCentralCrossRefGoogle Scholar
  208. 208.
    Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M et al (1992) Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 11(2):99–109PubMedCrossRefPubMedCentralGoogle Scholar
  209. 209.
    Jones JM (1990) Laboratory diagnosis of invasive candidiasis. Clin Microbiol Rev 3(1):32–45PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Ness MJ, Vaughan WP, Woods GL (1989) Candida antigen latex test for detection of invasive candidiasis in immunocompromised patients. J Infect Dis 159(3):495–502PubMedCrossRefPubMedCentralGoogle Scholar
  211. 211.
    Ruhnke M, Böhme A, Buchheidt D, Donhuijsen K, Einsele H, Enzensberger R et al (2003) Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S141–S148PubMedCrossRefPubMedCentralGoogle Scholar
  212. 212.
    Lee A, Mirrett S, Reller LB, Weinstein MP (2007) Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 45(11):3546–3548PubMedPubMedCentralCrossRefGoogle Scholar
  213. 213.
    Horvath LL, George BJ, Hospenthal DR (2007) Detection of fifteen species of Candida in an automated blood culture system. J Clin Microbiol 45(9):3062–3064PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Horvath LL, George BJ, Murray CK, Harrison LS, Hospenthal DR (2004) Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J Clin Microbiol 42(1):115–118PubMedPubMedCentralCrossRefGoogle Scholar
  215. 215.
    Fricker-Hidalgo H, Lebeau B, Pelloux H, Grillot R (2004) Use of the BACTEC 9240 system with mycosis-IC/F blood culture bottles for detection of fungemia. J Clin Microbiol 42(4):1855–1856PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Jensen J, Munoz P, Guinea J, Rodriguez-Creixems M, Pelaez T, Bouza E (2007) Mixed fungemia: incidence, risk factors, and mortality in a general hospital. Clin Infect Dis 44(12):e109–e114PubMedCrossRefPubMedCentralGoogle Scholar
  217. 217.
    Bouza E, Alcala L, Munoz P, Martin-Rabadan P, Guembe M, Rodriguez-Creixems M (2013) Can microbiologists help to assess catheter involvement in candidaemic patients before removal? Clin Microbiol Infect 19(2):E129–E135PubMedCrossRefPubMedCentralGoogle Scholar
  218. 218.
    Bouza E, Burillo A, Munoz P, Guinea J, Marin M, Rodriguez-Creixems M (2013) Mixed bloodstream infections involving bacteria and Candida spp. J Antimicrob Chemother 68(8):1881–1888PubMedCrossRefPubMedCentralGoogle Scholar
  219. 219.
    Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D et al (2002) Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51(5):433–442PubMedCrossRefPubMedCentralGoogle Scholar
  220. 220.
    Sendid B, Caillot D, Baccouch-Humbert B, Klingspor L, Grandjean M, Bonnin A et al (2003) Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 41(10):4551–4558PubMedPubMedCentralCrossRefGoogle Scholar
  221. 221.
    Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ et al (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39(2):199–205PubMedCrossRefPubMedCentralGoogle Scholar
  222. 222.
    Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F et al (2005) Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41(5):654–659PubMedCrossRefPubMedCentralGoogle Scholar
  223. 223.
    Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W (2009) Invasive fungal infections and (1,3)-beta-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 13(6):707–712PubMedCrossRefPubMedCentralGoogle Scholar
  224. 224.
    Posteraro B, De PG, Tumbarello M, Torelli R, Pennisi MA, Bello G et al (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-->3)-beta-D-glucan assay, Candida score, and colonization index. Crit Care 15(5):R249PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Shepard JR, Addison RM, Alexander BD, la-Latta P, Gherna M, Haase G et al (2008) Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 46(1):50–55PubMedCrossRefPubMedCentralGoogle Scholar
  226. 226.
    Marklein G, Josten M, Klanke U, Muller E, Horre R, Maier T et al (2009) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 47(9):2912–2917PubMedPubMedCentralCrossRefGoogle Scholar
  227. 227.
    Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA et al (2015) T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60(6):892–899CrossRefGoogle Scholar
  228. 228.
    Zacharioudakis IM, Zervou FN, Mylonakis E (2018) T2 magnetic resonance assay: overview of available data and clinical implications. J Fungi 4(2):E45CrossRefGoogle Scholar
  229. 229.
    Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH (2005) Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33(9):1928–1935PubMedCrossRefPubMedCentralGoogle Scholar
  230. 230.
    Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37PubMedCrossRefPubMedCentralGoogle Scholar
  231. 231.
    Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S et al (2008) Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149(2):83–90PubMedCrossRefPubMedCentralGoogle Scholar
  232. 232.
    Cui N, Wang H, Su L, Qiu H, Li R, Liu D (2017) Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study. BMC Infect Dis 17(1):93PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
    Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S et al (2010) Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 10:150PubMedPubMedCentralCrossRefGoogle Scholar
  234. 234.
    Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366(9495):1435–1442PubMedCrossRefPubMedCentralGoogle Scholar
  235. 235.
    Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7):883–893PubMedCrossRefPubMedCentralGoogle Scholar
  236. 236.
    Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482PubMedCrossRefPubMedCentralGoogle Scholar
  237. 237.
    Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G et al (2013) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93(1):13–32PubMedPubMedCentralCrossRefGoogle Scholar
  238. 238.
    Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A et al (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 102(3):433–444PubMedPubMedCentralCrossRefGoogle Scholar
  239. 239.
    Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW et al (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47(10):3149–3154PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ (2005) In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 43(11):5425–5427PubMedPubMedCentralCrossRefGoogle Scholar
  241. 241.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331(20):1325–1330Google Scholar
  242. 242.
    Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36(10):1221–1228PubMedCrossRefPubMedCentralGoogle Scholar
  243. 243.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527CrossRefGoogle Scholar
  244. 244.
    Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W et al (2014) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15(8):e327–e340PubMedCrossRefPubMedCentralGoogle Scholar
  245. 245.
    Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G et al (2012) Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 18(7):680–687PubMedPubMedCentralCrossRefGoogle Scholar
  246. 246.
    Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ et al (2009) A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48(12):1676–1684PubMedCrossRefPubMedCentralGoogle Scholar
  247. 247.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020):760–769PubMedPubMedCentralCrossRefGoogle Scholar
  248. 248.
    Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR et al (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828–837PubMedCrossRefPubMedCentralGoogle Scholar
  249. 249.
    Centers for Disease Control and Prevention (2013) Antibiotic resistance threats in the United States. 1-114. 16-9-2013. 1600 Clifton Rd. Atlanta, GA 30333, USA, Centers for Disease Control and Prevention. Ref Type: Internet CommunicationGoogle Scholar
  250. 250.
    Tacconelli E, Cataldo MA, Dancer SJ, De AG, Falcone M, Frank U et al (2014) ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20(Suppl 1):1–55PubMedCrossRefPubMedCentralGoogle Scholar
  251. 251.
    Pittet D (2001) Compliance with hand disinfection and its impact on hospital-acquired infections. J Hosp Infect 48(Suppl A):S40–S46PubMedCrossRefPubMedCentralGoogle Scholar
  252. 252.
    Zingg W, Imhof A, Maggiorini M, Stocker R, Keller E, Ruef C (2009) Impact of a prevention strategy targeting hand hygiene and catheter care on the incidence of catheter-related bloodstream infections. Crit Care Med 37(7):2167–2173PubMedCrossRefGoogle Scholar
  253. 253.
    Clark TA, Slavinski SA, Morgan J, Lott T, rthington-Skaggs BA, Brandt ME et al (2004) Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 42(10):4468–4472PubMedPubMedCentralCrossRefGoogle Scholar
  254. 254.
    Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R (1994) High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 32(9):2299–2300PubMedPubMedCentralGoogle Scholar
  255. 255.
    Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA et al (2013) Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 368(6):533–542PubMedPubMedCentralCrossRefGoogle Scholar
  256. 256.
    MacDougall C, Polk RE (2005) Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 18(4):638–656PubMedPubMedCentralCrossRefGoogle Scholar
  257. 257.
    Ruhnke M (2014) Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 20(Suppl 6):11–18PubMedCrossRefPubMedCentralGoogle Scholar
  258. 258.
    Jones TM, Drew RH, Wilson DT, Sarubbi C, Anderson DJ (2017) Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center. Am J Health Syst Pharm 74(23):1997–2003PubMedCrossRefPubMedCentralGoogle Scholar
  259. 259.
    Ostrosky-Zeichner L (2003) New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 16(6):533–537PubMedCrossRefPubMedCentralGoogle Scholar
  260. 260.
    Penk A, Pittrow L (1998) Status of fluconazole in the therapy of endogenous Candida endophthalmitis. Mycoses 41(Suppl 2):41–44PubMedPubMedCentralGoogle Scholar
  261. 261.
    Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139(1):135–140PubMedCrossRefPubMedCentralGoogle Scholar
  262. 262.
    Nasser RM, Melgar GR, Longworth DL, Gordon SM (1997) Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 103(1):25–32PubMedCrossRefPubMedCentralGoogle Scholar
  263. 263.
    Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G et al (2007) Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60(2):363–369PubMedCrossRefPubMedCentralGoogle Scholar
  264. 264.
    Kujath P, Lerch K, Kochendorfer P, Boos C (1993) Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 21(6):376–382PubMedCrossRefPubMedCentralGoogle Scholar
  265. 265.
    Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W et al (1996) A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 24(6):426–432PubMedCrossRefGoogle Scholar
  266. 266.
    Penk A, Pittrow L (1998) Fungal arthritis--a rare complication of systemic candidiasis or orthopedic intervention. Review of therapeutic experience with fluconazole. Mycoses 41(Suppl 2):45–48PubMedCrossRefGoogle Scholar
  267. 267.
    Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX et al (2005) Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40(8):1141–1147PubMedCrossRefGoogle Scholar
  268. 268.
    Fan-Havard P, O’Donovan C, Smith SM, Oh J, Bamberger M, Eng RH (1995) Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 21(4):960–965PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Markus Ruhnke
    • 1
  1. 1.Department of Haematology and OncologyParacelsus-KlinikOsnabrückGermany

Personalised recommendations